• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Fatty Liver Disease - Pipeline Review, Q4 2010 - Product Image

Fatty Liver Disease - Pipeline Review, Q4 2010

  • ID: 1464259
  • December 2010
  • 38 pages
  • Global Markets Direct

Fatty Liver Disease - Pipeline Review, Q4 2010

Summary

Global Markets Direct’s, “Fatty Liver Disease Pipeline Review, Q4 2010”, provides an overview of the Fatty Liver Disease therapeutic pipeline. This report provides information on the therapeutic development for Fatty Liver Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatty Liver Disease. “Fatty Liver Disease-Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- A snapshot of the global therapeutic scenario for Fatty Liver Disease.
- A review of the Fatty Liver Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fatty Liver Disease Overview
Therapeutics Development
An Overview of Pipeline Products for Fatty Liver Disease
Fatty Liver Disease Therapeutics under Development by Companies
Fatty Liver Disease Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Companies Involved in Fatty Liver Disease Therapeutics Development
Phynova Group Ltd
7TM Pharma A/S
Jenken Biosciences, Inc
Galmed International Ltd.
Universities/Institutes Involved in Fatty Liver Disease Therapeutics Development
Fatty Liver Disease Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Universities/Institutes
Exenatide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gabapentin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Midodrine + Octreotide + Human albumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-Adenosylmethionine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Fatty Liver Disease - Featured News
Oct 14, 2010: Galmed Initiates Phase II Clinical Trial Of Aramchol For Treatment Of Fatty Liver Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos